191 related articles for article (PubMed ID: 38340342)
61. Topoisomerase I inhibitors: Challenges, progress and the road ahead.
Talukdar A; Kundu B; Sarkar D; Goon S; Mondal MA
Eur J Med Chem; 2022 Jun; 236():114304. PubMed ID: 35413618
[TBL] [Abstract][Full Text] [Related]
62. Differential and common DNA repair pathways for topoisomerase I- and II-targeted drugs in a genetic DT40 repair cell screen panel.
Maede Y; Shimizu H; Fukushima T; Kogame T; Nakamura T; Miki T; Takeda S; Pommier Y; Murai J
Mol Cancer Ther; 2014 Jan; 13(1):214-20. PubMed ID: 24130054
[TBL] [Abstract][Full Text] [Related]
63. Design, synthesis and evaluation of thiohydantoin derivatives as potent topoisomerase I (Top1) inhibitors with anticancer activity.
Majumdar P; Bathula C; Basu SM; Das SK; Agarwal R; Hati S; Singh A; Sen S; Das BB
Eur J Med Chem; 2015 Sep; 102():540-51. PubMed ID: 26312433
[TBL] [Abstract][Full Text] [Related]
64. Lipid-derived electrophiles mediate the effects of chemotherapeutic topoisomerase I poisons.
Flor A; Wolfgeher D; Li J; Hanakahi LA; Kron SJ
Cell Chem Biol; 2021 Jun; 28(6):776-787.e8. PubMed ID: 33352117
[TBL] [Abstract][Full Text] [Related]
65. Repair of topoisomerase 1-induced DNA damage by tyrosyl-DNA phosphodiesterase 2 (TDP2) is dependent on its magnesium binding.
Shimizu N; Hamada Y; Morozumi R; Yamamoto J; Iwai S; Sugiyama KI; Ide H; Tsuda M
J Biol Chem; 2023 Aug; 299(8):104988. PubMed ID: 37392847
[TBL] [Abstract][Full Text] [Related]
66. Par-4 binds to topoisomerase 1 and attenuates its DNA relaxation activity.
Goswami A; Qiu S; Dexheimer TS; Ranganathan P; Burikhanov R; Pommier Y; Rangnekar VM
Cancer Res; 2008 Aug; 68(15):6190-8. PubMed ID: 18676842
[TBL] [Abstract][Full Text] [Related]
67. Silatecan DB-67 is a novel DNA topoisomerase I-targeted radiation sensitizer.
Chen AY; Shih SJ; Garriques LN; Rothenberg ML; Hsiao M; Curran DP
Mol Cancer Ther; 2005 Feb; 4(2):317-24. PubMed ID: 15713902
[TBL] [Abstract][Full Text] [Related]
68. G-quadruplex resolution: From molecular mechanisms to physiological relevance.
Sato K; Knipscheer P
DNA Repair (Amst); 2023 Oct; 130():103552. PubMed ID: 37572578
[TBL] [Abstract][Full Text] [Related]
69. Reversible Top1 cleavage complexes are stabilized strand-specifically at the ribosomal replication fork barrier and contribute to ribosomal DNA stability.
Krawczyk C; Dion V; Schär P; Fritsch O
Nucleic Acids Res; 2014 Apr; 42(8):4985-95. PubMed ID: 24574527
[TBL] [Abstract][Full Text] [Related]
70. Synthesis and biological evaluation of new fluorinated and chlorinated indenoisoquinoline topoisomerase I poisons.
Beck DE; Lv W; Abdelmalak M; Plescia CB; Agama K; Marchand C; Pommier Y; Cushman M
Bioorg Med Chem; 2016 Apr; 24(7):1469-79. PubMed ID: 26906474
[TBL] [Abstract][Full Text] [Related]
71. Interaction of human nuclear topoisomerase I with guanosine quartet-forming and guanosine-rich single-stranded DNA and RNA oligonucleotides.
Marchand C; Pourquier P; Laco GS; Jing N; Pommier Y
J Biol Chem; 2002 Mar; 277(11):8906-11. PubMed ID: 11756434
[TBL] [Abstract][Full Text] [Related]
72. Evaluation of two models for human topoisomerase I interaction with dsDNA and camptothecin derivatives.
Laco GS
PLoS One; 2011; 6(8):e24314. PubMed ID: 21912628
[TBL] [Abstract][Full Text] [Related]
73. DNA topoisomerase 1 and 2A function as oncogenes in liver cancer and may be direct targets of nitidine chloride.
Liu LM; Xiong DD; Lin P; Yang H; Dang YW; Chen G
Int J Oncol; 2018 Nov; 53(5):1897-1912. PubMed ID: 30132517
[TBL] [Abstract][Full Text] [Related]
74. Human topoisomerase I inhibition: docking camptothecin and derivatives into a structure-based active site model.
Laco GS; Collins JR; Luke BT; Kroth H; Sayer JM; Jerina DM; Pommier Y
Biochemistry; 2002 Feb; 41(5):1428-35. PubMed ID: 11814334
[TBL] [Abstract][Full Text] [Related]
75. Mammalian DNA topoisomerase I activity and poisoning by camptothecin are inhibited by simian virus 40 large T antigen.
Pommier Y; Kohlhagen G; Wu C; Simmons DT
Biochemistry; 1998 Mar; 37(11):3818-23. PubMed ID: 9521701
[TBL] [Abstract][Full Text] [Related]
76. AID-induced decrease in topoisomerase 1 induces DNA structural alteration and DNA cleavage for class switch recombination.
Kobayashi M; Aida M; Nagaoka H; Begum NA; Kitawaki Y; Nakata M; Stanlie A; Doi T; Kato L; Okazaki IM; Shinkura R; Muramatsu M; Kinoshita K; Honjo T
Proc Natl Acad Sci U S A; 2009 Dec; 106(52):22375-80. PubMed ID: 20018730
[TBL] [Abstract][Full Text] [Related]
77. Synthesis, cytotoxicity and structure-activity relationship of indolizinoquinolinedione derivatives as DNA topoisomerase IB catalytic inhibitors.
Yu Q; Yang H; Zhu TW; Yu LM; Chen JW; Gu LQ; Huang ZS; An LK
Eur J Med Chem; 2018 May; 152():195-207. PubMed ID: 29705710
[TBL] [Abstract][Full Text] [Related]
78. Synthetic lethal targeting of TET2-mutant hematopoietic stem and progenitor cells (HSPCs) with TOP1-targeted drugs and PARP1 inhibitors.
Jing CB; Fu C; Prutsch N; Wang M; He S; Look AT
Leukemia; 2020 Nov; 34(11):2992-3006. PubMed ID: 32572188
[TBL] [Abstract][Full Text] [Related]
79. Camptothecins and topoisomerase I: a foot in the door. Targeting the genome beyond topoisomerase I with camptothecins and novel anticancer drugs: importance of DNA replication, repair and cell cycle checkpoints.
Pommier Y
Curr Med Chem Anticancer Agents; 2004 Sep; 4(5):429-34. PubMed ID: 15379698
[TBL] [Abstract][Full Text] [Related]
80. Identification of G-quadruplex clusters by high-throughput sequencing of whole-genome amplified products with a G-quadruplex ligand.
Yoshida W; Saikyo H; Nakabayashi K; Yoshioka H; Bay DH; Iida K; Kawai T; Hata K; Ikebukuro K; Nagasawa K; Karube I
Sci Rep; 2018 Feb; 8(1):3116. PubMed ID: 29449667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
